<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04757714</url>
  </required_header>
  <id_info>
    <org_study_id>CHRO-2020-05</org_study_id>
    <nct_id>NCT04757714</nct_id>
  </id_info>
  <brief_title>Thoracic Kyphosis and Osteoporosis: Study of Their Relationship With Respiratory Functions in Chronic Obstructive Pulmonary Disease.</brief_title>
  <acronym>CYPHOS</acronym>
  <official_title>Thoracic Kyphosis and Osteoporosis: Study of Their Relationship With Respiratory Functions in Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Régional d'Orléans</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Régional d'Orléans</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a condition characterized by a progressive&#xD;
      and incompletely reversible limitation of airborne gas flow . The association of&#xD;
      co-morbidities with COPD and acute flare-ups of respiratory failure contribute to the overall&#xD;
      severity of this disease. The prevalence of COPD is high, affecting up to 10% of people over&#xD;
      the age of 40 years and causing high morbidity and mortality rates. While COPD is a disease&#xD;
      primarily affecting the lungs, it is associated with many extra-pulmonary conditions&#xD;
      including sleep apnea, depression, anemia, chronic kidney failure, wasting, cardiovascular&#xD;
      disease, skeletal muscle weakness and osteoporosis (OP).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis, characterized by bone quality disorders and low bone mineral density (BMD)&#xD;
      leading to a high risk of fractures, is common in COPD patients. For example, studies have&#xD;
      reported OP rates ranging from 9% to 69% in COPD patients. The explanatory factors for this&#xD;
      low BMD are clearly multiple, involving to varying degrees of importance, vitamin D&#xD;
      deficiency, depression, sedentary lifestyle, smoking, corticosteroids, low lean body mass and&#xD;
      body mass index, chronic inflammation, low nutritional status, chronic hypoxia and&#xD;
      hypercapnia. This is why patients with COPD have a high prevalence of fractures, particularly&#xD;
      vertebral fractures (VF) ranging from 30 to 63% depending on the studies. In these patients&#xD;
      the existence of thoracic VF is of crucial importance, as each VF is associated with a 9%&#xD;
      decrease in the forced vital capacity of COPD patients.&#xD;
&#xD;
      For these reasons the latest HAS recommendations for COPD management indicate that the risk&#xD;
      of osteoporosis should be systematically investigated and treated (HAS, 2014).&#xD;
&#xD;
      However, the relationship between densitometric variations and the presence of thoracic VF&#xD;
      and the prognosis and severity of the disease is not yet very clear, as studies of these&#xD;
      relationships have produced mixed results.&#xD;
&#xD;
      On the other hand, it is well established that patients with a recent diagnosis of COPD have&#xD;
      a high prevalence of densitometric OPs and fractures.&#xD;
&#xD;
      Thoracic kyphosis is one of the determinants of the incidence of vertebral fractures.&#xD;
      Increased thoracic kyphosis is associated with decreased physical capacity, increased risk of&#xD;
      falls and abnormal respiratory function.&#xD;
&#xD;
      In addition, measurement of thoracic kyphosis was previously carried out either indirectly&#xD;
      using point coordinates recorded in a database (patients were assessed in the supine&#xD;
      position) or more directly using a ruler applied against the back.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The thoracic kyphosis index</measure>
    <time_frame>Day 0</time_frame>
    <description>The kyphosis index will be used to assess thoracic kyphosis at the beginning of the study. This index is a percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced vital capacity</measure>
    <time_frame>Day 0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of densitometric osteoporosis</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of intermediate bone density</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of maximum expiratory volume per second (FEV1), percentage predicted value</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predicted value FEV1/Forced Vital Capacity</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score (St George Hospital questionnaire)</measure>
    <time_frame>Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity index of Osteoporosis</measure>
    <time_frame>Day 0</time_frame>
    <description>raw BMD values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity index of Osteoporosis</measure>
    <time_frame>Day 0</time_frame>
    <description>FRAX score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity index of Osteoporosis</measure>
    <time_frame>Day 0</time_frame>
    <description>number of VFs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) severity index</measure>
    <time_frame>Day 0</time_frame>
    <description>maximum expiratory volume per second (FEV1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) severity index</measure>
    <time_frame>Day 0</time_frame>
    <description>severity stage by the Global Initiative for Chronic Obstruction Lung Disease (GOLD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) severity index</measure>
    <time_frame>Day 0</time_frame>
    <description>prognosis stage according to BODE index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parameters measured by HRpQCT</measure>
    <time_frame>Day 0</time_frame>
    <description>volume density and microarchitecture</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Densitometric osteoporosis status</measure>
    <time_frame>Day 0</time_frame>
    <description>The status will be determine between: Osteoporosis , intermediate bone density and normal</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>COPD</condition>
  <condition>Osteoporosis</condition>
  <condition>Kyphosis</condition>
  <arm_group>
    <arm_group_label>COPD Patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients agreeing to participate in the study and meeting the inclusion and non-inclusion criteria will have:&#xD;
The high-resolution peripheral scanner (HRpQCT) of the tibia and radius&#xD;
a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)&#xD;
to complete:&#xD;
a physical activity questionnaire (PHAS instrument)&#xD;
a COPD quality of life questionnaire (St George Hospital)&#xD;
A search for sarcopenia by studying the strength of the grip (dynamometer)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>The high-resolution peripheral scanner (HRpQCT) of the tibia and radius</intervention_name>
    <description>The high-resolution peripheral scanner (HRpQCT) of the tibia and radius</description>
    <arm_group_label>COPD Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)</intervention_name>
    <description>a low-dose imaging system exploration of their thoraco-lumbar spine (EOS system)</description>
    <arm_group_label>COPD Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>a physical activity questionnaire (PHAS instrument)&#xD;
a COPD quality of life questionnaire (St George Hospital)</description>
    <arm_group_label>COPD Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A search for sarcopenia by studying the strength of the grip (dynamometer)</intervention_name>
    <description>A search for sarcopenia by studying the strength of the grip (dynamometer)</description>
    <arm_group_label>COPD Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman age &gt; 40&#xD;
&#xD;
          -  FEV1/CVF ratio &lt; 0.7 as defined by the Global Initiative for Chronic Obstruction Lung&#xD;
             Disease (GOLD).&#xD;
&#xD;
          -  Moderate to severe COPD as defined by GOLD (grade C and D)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of metal or plastic parts in the field of examination&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients who are not affiliated with or do not benefit from a social security system&#xD;
&#xD;
          -  Person under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric LESPESSSAILLES, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHR ORLEANS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurélie DESPUJOLS</last_name>
    <phone>+33238744071</phone>
    <email>aurelie.despujols@chr-orleans.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie POUGOUE TOUKO</last_name>
    <phone>+33238744086</phone>
    <email>elodie.pougoue-touko@chr-orleans.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHR d'ORLEANS</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eric LESPESSAILLES, Ph</last_name>
      <email>eric.lespessailles@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Eric LESPESSAILLES, Ph</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004 Mar 4;350(10):1005-12.</citation>
    <PMID>14999112</PMID>
  </reference>
  <reference>
    <citation>Cielen N, Maes K, Gayan-Ramirez G. Musculoskeletal disorders in chronic obstructive pulmonary disease. Biomed Res Int. 2014;2014:965764. doi: 10.1155/2014/965764. Epub 2014 Mar 25. Review.</citation>
    <PMID>24783225</PMID>
  </reference>
  <reference>
    <citation>Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012 Apr 7;379(9823):1341-51. doi: 10.1016/S0140-6736(11)60968-9. Epub 2012 Feb 6. Review.</citation>
    <PMID>22314182</PMID>
  </reference>
  <reference>
    <citation>Eagan TM, Aukrust P, Ueland T, Hardie JA, Johannessen A, Mollnes TE, Damås JK, Bakke PS, Wagner PD. Body composition and plasma levels of inflammatory biomarkers in COPD. Eur Respir J. 2010 Nov;36(5):1027-33. doi: 10.1183/09031936.00194209. Epub 2010 Apr 22.</citation>
    <PMID>20413541</PMID>
  </reference>
  <reference>
    <citation>Ekblom Ö, Ekblom-Bak E, Bolam KA, Ekblom B, Schmidt C, Söderberg S, Bergström G, Börjesson M. Concurrent and predictive validity of physical activity measurement items commonly used in clinical settings--data from SCAPIS pilot study. BMC Public Health. 2015 Sep 28;15:978. doi: 10.1186/s12889-015-2316-y.</citation>
    <PMID>26415512</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Kyphosis</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

